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Introduction
ETV6, the E26 transformation-specific (ETS) family transcription repressor and tumor suppressor variant 6 
gene, resides on chromosome 12p13 and encodes a 57 kDa ETS family transcription factor with 3 highly con-
served functional domains (1, 2): an N-terminal pointed (PNT) dimerization domain, a central linker domain, 
and an 85–amino acid C-terminal ETS DNA-binding domain, which associates with the 5′GGA(A/T)3′ 
motif  in the promoter region of  target genes (2). The ETS family of  transcription factors represents a vast 
network of  inter- and intramolecular interactions that result in combinatorial regulation of  gene expression 
(2–7). Dimerization of  ETV6 through the PNT domain facilitates cooperative DNA binding and transcrip-
tional regulatory activity (8). While ETV6 is known to dimerize to achieve its transcriptional function, it has 
been reported to associate with other corepressors, such as HDAC3, NCOR, and Sin3 (9). Indeed, molecular 
models have defined ETV6 as a transcriptional repressor (9–12), likely via its interaction with HDAC-related 
corepressors (9, 12, 13).
ETV6 is a well-studied hematopoietic transcription factor previously reported to play a key functional 
role in hematopoiesis, megakaryopoiesis, cell growth, and differentiation (11, 14–16). Previous studies in 
mouse models indicate that ETV6 is necessary for normal hematopoiesis (14, 16, 17). As such, global dele-
tion of  Etv6 in mice results in embryonic lethality between E10.5 and E11.5, with yolk sac angiogenic defects 
(16, 17). Conditional knockout of  Etv6 in megakaryocyte (MK) erythroid progenitor cells in mice results in 
thrombocytopenia, with an increased frequency of  MK colony-forming cells (14). These findings are consis-
tent with a terminal defect in MK maturation, leading to a compensatory increase in MK progenitor cells. 
Etv6 controls the survival of  hematopoietic stem cells (HSCs) and is required late in the development of  
ETV6 is an ETS family transcription factor that plays a key role in hematopoiesis and 
megakaryocyte development. Our group and others have identified germline mutations in ETV6 
resulting in autosomal dominant thrombocytopenia and predisposition to malignancy; however, 
molecular mechanisms defining the role of ETV6 in megakaryocyte development have not been well 
established. Using a combination of molecular, biochemical, and sequencing approaches in patient-
derived PBMCs, we demonstrate abnormal cytoplasmic localization of ETV6 and the HDAC3/NCOR2 
repressor complex that led to overexpression of HDAC3-regulated interferon response genes. This 
transcriptional dysregulation was also reflected in patient-derived platelet transcripts and drove 
aberrant proplatelet formation in megakaryocytes. Our results suggest that aberrant transcription 
may predispose patients with ETV6 mutations to bone marrow inflammation, dysplasia, and 
megakaryocyte dysfunction.
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MKs, where it may be acting in concert with other transcriptional regulators of  megakaryopoiesis to bind 
MK-specific promoters (14). In human studies, ETV6 has been shown to regulate the expression of  platelet 
and MK-specific proteins, such as MK/platelet glycoprotein 1bα (GP1BA) and glycoprotein IX (GP9) (18, 19). 
Furthermore, ETV6 interacts with FLI1 (18), another ETS transcription factor and master regulator of  MK 
development. FLI1 haploinsufficiency results in Paris-Trousseau syndrome, another heritable form of throm-
bocytopenia (20). Thus, ETV6 is known to have a critical role in MK development and platelet production.
We and others have identified heterozygous germline ETV6 mutations as the cause for dominantly inher-
ited thrombocytopenia in several families (11, 15). The majority of  the mutations reported to date occur in 
the ETS DNA-binding domain, where they have been shown to decrease DNA-binding capacity (12). The 
p.Pro214Leu mutation in the central domain is the most commonly identified mutation outside of  the ETS 
domain, occurring in 5 unique families (21). Deletions in the ETS domain have also been described, resulting 
in protein truncation as a consequence of  alternative splicing (22, 23). In cell lines and overexpression models, 
missense mutations in the central domain and the ETS DNA-binding domain of  ETV6 result in aberrant 
cytoplasmic localization, decreased transcriptional repression, and impaired MK maturation (11, 15). The 
bone marrow of these affected individuals shows erythroid dysplasia and hyperplasia of  small, hypolobu-
lated, immature MKs, suggesting incomplete differentiation and inability to release platelets into circulation 
(11). Despite these recent advancements in the field, the precise molecular mechanisms underpinning throm-
bocytopenia and cancer predisposition in patients with ETV6 mutations have yet to be defined.
In this study, we sought to define the role of  ETV6 in human blood cells and understand the cellu-
lar and transcriptional consequences of  ETV6 germline mutations. We used PBMCs from healthy con-
trols and patients carrying germline mutations in the central domain (p.ProP214Leu; P214L) and the ETS 
DNA-binding domain (p.Arg369Gln; R369Q) to investigate the subcellular localization, protein-protein 
interactions, and transcriptional targets of  ETV6. Here, we demonstrate abnormal subcellular distribution 
of  ETV6 and the HDAC3/NCOR2 repressor complex. This cytoplasmic mislocalization leads to upregu-
lation of  proinflammatory interferon response genes, which are regulated by HDAC3 (24). We also interro-
gated the consequence of  cytoplasmic ETV6 in MK development and demonstrated aberrantly upregulated 
proinflammatory transcripts in platelet mRNA expression profiles from patients carrying the ETV6 P214L 
allele. We further confirmed this transcriptional signature by ablating nuclear ETV6 in MKs and show 
increased proinflammatory interferon response gene expression and significantly reduced proplatelet for-
mation. Taken together, these data demonstrate that ETV6 is required for homeostatic MK programing and 
differentiation through its association with HDAC3/NCOR2. Nuclear exclusion of  ETV6 shifts the cellu-
lar balance of  histone and protein acetylation, altering the epigenetic landscape and derepressing interferon 
response genes. Aberrant gene expression in MKs results in defective proplatelet formation, underpinning 
the thrombocytopenia observed in patients with germline mutations in ETV6.
Results
Germline ETV6 mutations cause cytoplasmic localization of  ETV6 in all nucleated blood cells. While mislocalization 
of  mutant ETV6 has been reported in overexpression models and cell lines (11, 15), this phenotype has 
not been validated in patient-derived cells expressing physiologic amounts of  ETV6. We performed immu-
nofluorescence studies to examine the subcellular localization of  ETV6 in PBMCs derived from healthy 
controls and patients carrying germline mutations in ETV6. In healthy control PBMCs, ETV6 was con-
centrated in the nucleus, colocalizing with DNA (Figure 1A). However, in patients carrying the germline 
mutations P214L and R369Q, ETV6 was concentrated in the cytoplasm (Figure 1A). Quantification of  
ETV6 fluorescence intensity in each subcellular compartment demonstrated a significant alteration of  the 
nuclear-to-cytoplasmic ratio of  ETV6 P214L (Figure 1B, unpaired t test, P < 0.0001). The statistical analysis 
of  R369Q samples was limited due to low cell numbers; however, the staining pattern was conserved. Mislo-
calized ETV6 was observed across all patient samples analyzed (n = 3 patients carrying ETV6 P214L [ETV6 
P214L patients] and patients carrying ETV6 R369Q mutations [ETV6 R369Q patients], respectively). These 
data indicate that mutant ETV6 is mislocalized to the cytoplasm in patient-derived PBMCs, in accordance 
with previous studies using overexpression tools and cell lines.
ETV6 associates with HDAC3 and mislocalizes the HDAC3/NCOR2 complex, resulting in increased histone 
acetylation. While the ETV6 PNT and ETS domains have been defined as the dimerization and DNA-binding 
regions, respectively (1, 10), the function of  the central domain of  ETV6 has been largely unexplored. 
Previous reports in overexpression models have shown interaction between the central domain of  ETV6 
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and transcriptional corepressors, such as HDAC3 and NCOR (9, 13). These components of  the ETV6 
transcriptional machinery have been proposed to act as corepressors of  ETV6 transcriptional targets (13). 
With our observation of  cytoplasmic ETV6 in patient-derived PBMCs, we hypothesized that cofactors we 
identified in a complex with ETV6 would also be mislocalized to the cytoplasm. Thus, we demonstrate 
by immunofluorescence staining of  HDAC3 (Figure 2A) a significant mislocalization to the cytoplasm 
mutant ETV6 in ETV6 P214L cells. Quantification of  HDAC3 fluorescence intensity in each subcellular 
compartment demonstrated a significant alteration of  the nuclear-to-cytoplasmic ratio (Figure 2B, unpaired 
t test, P = 0.0071). We further demonstrated altered subcellular localization when examining NCOR2 in 
the patient-derived PBMCs (Figure 2C). Quantification of  fluorescence intensity of  NCOR2 in each sub-
cellular compartment demonstrated a significant alteration of  the nuclear-to-cytoplasmic ratio of  NCOR2 
in ETV6 P214L cells (Figure 2D, unpaired t test, 0.0169). We validated the biochemical interaction of  this 
complex in primary PBMCs derived from healthy controls and showed by coimmunoprecipitation a robust 
protein-protein interaction among ETV6, HDAC3, and NCOR2 in PBMCs expressing WT ETV6 (Fig-
ure 2E; see complete unedited blots in the supplemental material). Previous studies using a two-hybrid 
approach demonstrate both WT and ETV6 P214L to associate with these nuclear corepressors (12), further 
confirming our observation of  this extranuclear transcriptional complex in patient-derived PBMCs.
We next hypothesized that cytoplasmic mislocalization of  the ETV6/HDAC3/NCOR2 transcriptional 
complex in PBMCs would result in increased histone acetylation due to loss of  nuclear HDAC3 activi-
ty. To recapitulate the lack of  nuclear ETV6 we observed in the patient-derived PBMCs, we significantly 
reduced the expression of  ETV6 in healthy control primary PBMCs using an siRNA-mediated knockdown 
of  ETV6 (P < 0.0001, Supplemental Figure 3A). We also ablated ETV6 expression in primary cord blood–
derived MKs using CRISPR-mediated deletion of  ETV6. We observed increased acetylation of  histone H3 
using both strategies in these unique primary cell types (Figure 2, F and G; see complete unedited blots in 
the supplemental material). The altered balance of  acetylated histone H3 in the absence of  nuclear ETV6 
indicates epigenetic changes driving transcriptional dysregulation in PBMCs.
Figure 1. Mislocalization of ETV6 P214L in all peripheral cell types. (A) Comparison via immunofluorescence microscopy of ETV6 localization in PBMCs 
from ETV6 P214L and R369Q patients and healthy controls. Representative PBMCS stained for DNA (blue) and ETV6 (green). In cells from healthy controls, 
ETV6 is concentrated in the nucleus. In contrast, cells from patients carrying ETV6 P214L and ETV6 R369Q demonstrated ETV6 concentrated in the 
cytoplasm, with scarce staining in the nucleus. Scale bar: 20 μm. Original magnification, ×8 (inset). (B) Nuclear-to-cytoplasmic intensity ratio of ETV6 is 
significantly reduced in ETV6 P214L PBMCs (unpaired t test, ****P < 0.0001). Fluorescence intensity was calculated in the nucleus and cytoplasm. n = 5 
random fields of view used to calculate N/C intensity ratio, representing over 100 cells analyzed in each condition.
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Cytoplasmic localization of  ETV6 in P214L and R369Q patient–derived PBMCs drives upregulation of  interferon 
response genes. We observed aberrant subcellular localization of  ETV6 and the HDAC3/NCOR2 complex 
in all PBMCs from patients with the P214L and R369Q mutations and increased histone acetylation when 
ETV6 expression was reduced in the nucleus in healthy PBMCs and cord blood–derived MKs. To deter-
mine the transcriptional consequence of  nuclear exclusion of  ETV6, we performed single-cell RNA-Seq of  
PBMCs from affected individuals carrying ETV6 P214L (n = 5 patients) and R369Q (n = 3 patients) muta-
tions and compared their gene expression with healthy age- and sex-matched controls (n = 6 donors and 
3 donors, respectively) (Figure 3A). Using well-defined surface markers and transcriptional signatures, we 
identified broad peripheral cell populations, such as B cells (MS4A1, CD19), T cells (IL7R, CCR7, S100A4), 
NK cells (GNLY, NKG7), and monocytes (CD14, LYZ, MS4A7), on the Uniform Manifold Approximation 
and Projection (UMAP) projection of  the cell clusters (Figure 3B) (25). We then used this data set to inves-
tigate transcriptional differences between patients and controls, and we detected upregulation of  204 genes 
representing a highly robust proinflammatory transcriptional signature. We analyzed the intersection of  the 
increased transcripts across these 4 populations (Figure 3C), which identified a highly specific suite of  22 
genes that were upregulated 4- to 400-fold depending on the cell type. These highly upregulated 22 tran-
scripts in the affected individuals were highly enriched for the interferon response pathway, consisting of  
proinflammatory transcripts, such as CCL4, CCL4L2, CCL3, CCL3L3, IFIT2, ISG15, MX1, IFIT3, IRF1, and 
NFKBIA, among others (Figure 3D). PBMC transcripts from ETV6 R369Q patients confirmed this result, 
with interferon response genes being upregulated in patient samples when compared with control cells 
(Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.140332DS1). Supporting our initial observations of  ETV6 interaction with the HDAC3/NCOR2 
complex, HDAC3 was confidently predicted by Ingenuity Pathway Analysis to be an upstream master regu-
lator of  this suite of  upregulated genes (Supplemental Figure 2). These observations suggest that ETV6 and 
HDAC3 coordinately regulate the expression of  interferon response genes.
To further confirm this observation, we used our siRNA knockdown model in healthy control PBMCs. 
Upon robust protein and mRNA knockdown of  ETV6 (Supplemental Figure 3A, Mann-Whitney U test, 
P > 0.0001), we subjected the PBMCs to RNA-Seq and performed differentially expressed gene (DEG) 
analysis on the control (untreated and nontargeting) and ETV6 knockdown samples (Supplemental Figure 
3B, 3 independent experiments). From this DEG analysis, we observed upregulation of  proinflammatory 
genes, such as CCL3, CCL7, IRF1, IRF4, IFIT2, and IL1B, among others when comparing our control sam-
ples to ETV6 knockdown samples. These results were not statistically significant due to the variability of  
ETV6 knockdown in primary cells between independent experiments. However, top canonical pathways 
identified by Ingenuity Pathway Analysis of  these DEGs demonstrated upregulated neutrophil/monocyte 
inflammation (TREM1 signaling, ref. 26), regulation of  macrophage inflammatory signaling (LXR/RXR 
activation, ref. 27, 28; iNOS signaling, ref. 29), and inflammatory cytokine signaling (IL-6 signaling, role 
of  IL17-F in allergic inflammation, ref. 30) (Supplemental Figure 3C). Taken together, these data indicate 
that nuclear ETV6 modulates the repression of  key inflammatory transcripts.
To control for frequency of  PBMCs and eliminate skewing of  transcriptional changes due to cell numbers, 
we used flow cytometry–based immunophenotyping to compare mutant ETV6 PBMCs to healthy controls. 
Figure 2. HDAC3/NCOR2 complex binds to ETV6 and is mislocalized in ETV6 P214L and R369Q PBMC, resulting in increased acetylation. (A) Comparison 
via immunofluorescence microscopy of HDAC3 localization in PBMCs from ETV6 P214L and R369Q patients and healthy controls. Representative PBMCs 
stained for DNA (blue) and HDAC3 (red). In cells from healthy controls, HDAC3 is concentrated in the nucleus. In contrast, cells from patients carrying ETV6 
P214L or R369Q demonstrated HDAC3 concentrated in the cytoplasm, with scarce staining in the nucleus. Scale bar: 20 μm. Original magnification, ×8 (inset). 
(B) Nuclear-to-cytoplasmic intensity ratio of HDAC3 is significantly reduced in ETV6 P214L PBMCs (unpaired t test, **P = 0.0071). Fluorescence intensity was 
calculated in the nucleus and cytoplasm. n = 5 random fields of view were used to calculate N/C intensity ratio, representing a minimum of 100 cells analyzed 
in each condition. (C) Comparison via immunofluorescence microscopy of NCOR2 localization in PBMCs from ETV6 P214L patients and healthy controls. Rep-
resentative PBMCs stained for DNA (blue) and cofactors listed above (red). In cells from healthy controls, NCOR2 is concentrated in the nucleus. In contrast, 
cells from patients carrying ETV6 P214L and R369Q demonstrated NCOR2 concentrated in the cytoplasm, with scarce staining in the nucleus. Scale bar: 20 
μm. Original magnification, ×8 (inset). (D) Nuclear-to-cytoplasmic intensity ratio of NCOR2 is significantly reduced in ETV6 P214L PBMCs (unpaired t test, *P = 
0.0169). Fluorescence intensity was calculated in the nucleus and cytoplasm. n = 5 random fields of view were used to calculate N/C intensity ratio, repre-
senting a minimum of 100 cells analyzed in each condition. (E) Immunoprecipitation of ETV6 in healthy control PBMCs demonstrates ETV6 interacting with 
HDAC3 and NCOR2. α-Tubulin was included to demonstrate equal loading of protein in each sample. Representative image of 2 independent experiments. (F) 
Transient knockdown of ETV6 by siRNA in healthy control PBMCs results in increased acetylated histone H3 compared with control conditions. Representative 
image of 2 independent experiments. (G) CRISPR-mediated knockout of ETV6 in cord blood–derived CD34+ HSCs drives increased acetylation of histone H3. 
Representative image of 2 independent experiments.
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Immunophenotyping of  both ETV6 P214L and ETV6 R369Q PBMCs demonstrated normal frequencies 
of  peripheral cell populations, including B and T cells (CD3+ and CD19+, respectively) and common lym-
phoid progenitors (CD19–CD3–CD34+CD10+) (Supplemental Figure 4). Of  note, the abundance of  periph-
eral circulating HSCs (CD34+, CD38–, CD90+) was significantly increased in patients carrying the ETV6 
P214L allele (Supplemental Figure 4A), which confirms previous observations of  increased circulating 
HSCs in other families carrying this mutation (12). ETV6 R369Q patients also had increased peripheral 
MK erythroid progenitors (CD10–CD34+CD38+CD135–CD45RA–) (Supplemental Figure 4B). To assess 
whether the inflammatory gene signature in ETV6 P214L PBMCs was associated with systemic inflamma-
tory cytokine production, we analyzed the cytokine profile of  the ETV6 P214L patients as compared with 
that of  healthy controls. However, we did not observe increased proinflammatory cytokines or chemokines 
in ETV6 P214L patients, suggesting that the transcriptional differences observed between the genotypes are 
a result of  mutated ETV6 and not due to another ongoing proinflammatory processes (Supplemental Fig-
ure 5). They also suggest the inflammatory gene signature may not directly translate to increased systemic 
cytokine production in ETV6 P214L patients.
Patient-derived ETV6 P214L platelets and MKs lacking nuclear ETV6 show upregulation of  interferon 
response genes and decreased proplatelet formation. Despite the well-defined association between germline 
mutations in ETV6 and thrombocytopenia, the transcriptional role of  ETV6 in human MK maturation 
and platelet production is still unknown. We hypothesized that patient-derived platelets would exhibit 
upregulation of  interferon response genes, as ETV6 is a ubiquitously expressed transcriptional repres-
sor in hematopoietic cells. Furthermore, we sought to understand the transcriptome-wide alterations 
caused by cytoplasmic mislocalization of  ETV6 during MK development. We compared the profile of  
platelet mRNA derived from patients carrying the ETV6 P214L allele (n = 2) to that of  healthy controls 
(n = 5, 2 unaffected relatives and 3 unrelated) and observed upregulation of  key interferon response 
genes, such as CCL3, CCL4, IL1RN, TNFAIP2/8, ISG15, IRF1/2/5/9, and MX1 (Figure 4A, adjusted 
P < 0.0001 for all genes displayed). Additionally, we observed 2 clusters of  downregulated transcripts 
that were identified by DAVID Functional Annotation Clustering (Supplemental Figure 6). The most 
enriched cluster included extracellular matrix and cell adhesion transcripts (enrichment score = 1.8), 
and the second-most enriched cluster included genes involved in cytoskeletal biology (enrichment 
score = 1.78). The differences we observed in the platelet transcriptome of  affected patients suggest 
that ETV6 plays a key role in megakaryopoiesis; however, the platelet transcriptome likely represents 
a snapshot of  the more complex MK transcriptional landscape. Thus, we confirmed the transcription-
al signature we observed in the patient-derived platelet transcripts in MKs by ablating ETV6 using 
CRISPR/Cas9 gene editing. We achieved ETV6 deletion in primary CD34+ cells derived from umbil-
ical cord blood and differentiated these cells into MKs as previously reported (11, 31) (Figure 4B; 
see complete unedited blots in the supplemental material). We compared the transcriptional profile 
of  cells expressing ETV6 to those lacking ETV6 (Figure 4C), and, similar to that in patient-derived 
platelets and PBMCs, we found upregulation of  proinflammatory transcripts, including key interferon 
response genes, such as CCL3, CCL3L3, CCL4, CCL4L2, and ILRN in ETV6-deficient MKs (Figure 
4C, representative heatmap of  1 experiment in a series of  3 independent experiments). Notably, we 
observed downregulation of  several cytoskeletal transcripts, such as TUBB2A, WNT11, ECM1, FLNB, 
MMP2, MYL4/9, and LIMA1, as was initially observed in the patient-derived platelets (Figure 4C). We 
further observed significantly decreased proplatelet formation in the ETV6-knockout MKs (Figure 4D, 
3 independent experiments, Mann-Whitney U test, P > 0.0001), demonstrating that ETV6 is required 
for functional megakaryopoiesis and platelet formation. Consistent with clinical findings in patients 
carrying germline ETV6 mutations (11, 12), MKs that lack nuclear ETV6 are similarly deficient in 
proplatelet formation. Collectively, these data suggest that ETV6 is required for homeostatic transcrip-
tional control in MKs, and the altered interferon and cytoskeletal gene programs we observed may 
predispose patients with ETV6 mutations to thrombocytopenia via decreased proplatelet formation.
Figure 3. Cytoplasmic localization of ETV6 in P214L and R369Q patient-derived PBMCs drives upregulation of interferon response genes. (A) UMAP plot 
of cells sequenced from healthy controls (blue) and ETV6 P214L patients (red). (B) UMAP plot of cells sequenced from healthy controls (circles) and ETV6 
P214L patients (triangles), denoting cell types. (C) Complex Venn diagram of upregulated genes across all 4 cell subsets, identifying a highly specific 22 
gene signature of proinflammatory interferon response genes (in red). (D) Dot plot of top differentially expressed interferon response genes, split by ETV6 
P214L patients versus age and sex matched controls.
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Figure 4. ETV6 P214L–derived platelets and MKs lacking nuclear ETV6 demonstrate transcriptional dysregulation 
and impaired proplatelet formation. (A) Proinflammatory interferon response genes are dysregulated in platelet 
transcripts from ETV6 P214L patients (n = 2) as compared with healthy controls (n = 5) (adjusted P > 0.0001 for all 
genes displayed). (B) Western blot demonstrating complete knockout of ETV6 protein mediated by CRISPR sgRNA. 
Representative of 2 independent experiments. Histone H3 loading control is previously shown in Figure 2G, as these 
experiments were conducted on the same set of knockout samples. (C) Transcriptional dysregulation of ETV6-knockout 
MK cells, upregulated genes enriched in the interferon response pathway, downregulated genes enriched in cytoskel-
etal biology. Heatmap displays mean transcript counts of 1 experiment in a series of 3 independent experiments. (D) 
Proplatelet formation is significantly impaired (Mann-Whitney U test, P < 0.0001, 3 independent experiments) when 
ETV6 is deleted in cord blood–derived MKs. CD34+ cells were differentiated into MKs, and proplatelet-forming cells were 
scored on day 12–14. More than 300 proplatelet-forming cells were counted per condition.
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Discussion
Here we describe 2 ETV6 germline mutations residing in distinct domains of  the protein that causes cyto-
plasmic mislocalization not only of  ETV6, but also of  the ETV6-associated HDAC3/NCOR2 complex, 
altering the transcriptional profile of  PBMCs and impairing MK proplatelet formation. The function of  
ETV6 has primarily been investigated with the use of  overexpression models, reporter plasmids, and cell 
lines. While these tools have been valuable in characterizing the structure and protein interactions of  ETV6, 
the transcriptional targets and physiologic role of  ETV6 had not yet been shown in patients.
Given our findings that ETV6 is mislocalized from the nucleus of  patient-derived PBMCs, we sought 
to define the transcriptome of  patients with germline ETV6 mutations. We demonstrated that ETV6 P214L 
and R369Q PBMCs had upregulated proinflammatory interferon response genes, which are known to be 
regulated by HDAC3 (24). We further showed that knockdown of  ETV6 in primary PBMCs and ablation of  
ETV6 in primary cord blood–derived MKs skews the balance of  acetylated histone H3. While these effects 
are likely cell-type specific, the increase in histone acetylation observed as a result of  ETV6 knockdown and/
or ablation demonstrates the functional consequence of  cytoplasmic ETV6, which is likely secondary to the 
inability of  HDAC3/NCOR2 to access nuclear targets. These findings suggest that nuclear ETV6 is required 
to direct the HDAC3/NCOR2 complex to interferon response promoters, and the lack of  deacetylation of  
these specific promoters, as seen by increased acetylated histone H3, is sufficient to derepress their transcrip-
tion. Importantly, patient-derived platelet transcripts demonstrate upregulation of  interferon response genes, 
and we also show that transcriptional dysregulation of  interferon response genes likewise occurs in primary 
cord blood–derived MKs that lack nuclear ETV6. Collectively, these data indicate that MKs of  patients with 
ETV6 germline mutations also exhibit this proinflammatory transcriptional signature.
ETV6 germline variants have been shown to reduce the transcriptional repressive activity of  ETV6 
(10). This loss of  repression can be attributed to the dominant negative effect of  the cytoplasmic mislo-
calization of  ETV6, whereby WT ETV6 dimerizes with mutant copies and is removed from the nucleus 
(11). However, ETV6 variants have been shown to mislocalize to the cytoplasm in different degrees 
(11, 15). We confirmed this with our findings in patient-derived PBMCs, in which ETV6 R369Q was 
observed to have a lesser degree of  cytoplasmic localization compared with ETV6 P214L, suggesting 
other potential mechanisms by which transcription is derepressed. Despite these findings, total protein 
levels of  ETV6 in P214L patient samples are equivalent to those in healthy controls (11). Indeed, some 
ETV6 variants have been also shown to reduce homeostatic transcriptional repression through decreased 
DNA-binding capacity (12, 15). Our findings of  increased interferon response gene expression in cells 
lacking nuclear ETV6 (both primary PBMCs and primary cord blood–derived MKs) suggest that nuclear 
ETV6 is required for HDAC3-mediated repression of  these key interferon response targets. Our conclu-
sions are supported by previous studies examining ETV6-binding sites, in which IRF motifs were highly 
represented in regions that were bound by ETV6 (32). Overall, our results indicate that genetic disruption 
of  ETV6 results in deregulation of  interferon response genes, perhaps generating a proinflammatory 
bone marrow environment that affects megakaryopoiesis and overall hematopoiesis, predisposing to the 
development of  myelodysplasia. Interestingly, an inflammatory bone marrow environment and predispo-
sition to myelodysplasia is also observed in patients with RUNX1 mutations (33), another key ETS tran-
scription factor involved in megakaryopoiesis. Aberrant innate immune activation plays a central role 
in the pathogenesis of  myelodysplastic syndrome (34), and gene expression profiles of  myelodysplastic 
CD34+ cells demonstrate upregulation of  interferon response genes (35). Altogether, this suggests that 
ETS dysfunction could play a role in the pathogenesis of  myelodysplasia. Ongoing studies in our labora-
tory are testing the hypothesis that MKs are critical for maintaining bone marrow homeostasis, perhaps 
acting as “gatekeepers” from dysregulated inflammation and subsequent myelodysplasia.
HDAC activity has been associated with normal MK maturation and platelet production. It has been 
proven critical for mass production of  platelets in vitro (36), and HDAC inhibitors (HDACi), widely used to 
treat malignancies, have been associated with thrombocytopenia, likely due to decreased megakaryopoiesis 
and thrombopoiesis (37). The mechanism for HDACi altering platelet production is poorly understood, but 
some have suggested either direct toxic effects on hematopoietic progenitor cells and late-stage MKs (37) or 
the inhibition of  proplatelet formation through increasing levels of  acetylated tubulin, subsequently alter-
ing the microtubule dynamics and organization required for proper proplatelet formation (38). Of  note, 
HDACi-treated MKs downregulate the expression of  notable hematopoietic transcription factors, includ-
ing GATA-1, NF-E2, and FLI1, among others (39). Other MK-specific studies demonstrate that treatment 
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with HDACi increased the number of  MK/erythroid progenitors, with an accompanied inhibition of  MK 
differentiation (40), which is similar to our observation that patients with ETV6 germline mutations showed 
small, immature, hypolobulated MKs (11) and increased progenitors in peripheral blood. Most importantly 
to our findings, pan-HDAC inhibition in primary MKs is associated with decreased proplatelet formation 
(37). In our study, we showed that cord blood–derived MKs lacking ETV6 exhibit decreased proplatelet 
formation, which is also observed in CD34+ derived MKs from ETV6 P214L patients (12) and cord blood–
derived MKs treated with HDACi (37), suggesting that ETV6 and HDAC3 in combination regulate key 
promoters required for proplatelet formation. These key targets are likely enriched in cytoskeletal biology, 
as proplatelet formation has been shown to be dependent on structural rearrangement (41–43).
In summary, our genetic and molecular studies in patient-derived PBMCs demonstrated a potential 
mechanism for ETV6-mediated thrombocytopenia and predisposition to hematopoietic malignancies. Our 
findings suggest that ETV6 is required for HDAC-mediated effects on MK differentiation, and the exclu-
sion of  ETV6 shifts the balance of  histone and protein acetylation, resulting in defective proplatelet for-
mation and clinical thrombocytopenia. These findings may have implications for the effects of  HDACi on 
patient platelet counts. Additionally, we have identified a subset of  differentially expressed mRNAs that 
encompass a large number of  interferon response genes, suggesting that ETV6 is relevant not only for MK 
development, but also bone marrow homeostasis.
Methods
Immunofluorescence. All ETV6 P214L patients in the cohort were recruited at the Hematology Clinic at 
Children’s Hospital of  Michigan. All ETV6 R369Q patients in the cohort were recruited at the Hematol-
ogy Clinic at Children’s Mercy Hospital. 100,000 PBMCs were resuspended in buffer (1× PBS [Gibco] 
supplemented with 5% FBS) and spun down on coated slides (Shandon Double Cytoslide, Thermo Fisher 
Scientific) using Shandon Cytospin (Thermo Fisher Scientific) at 350g for 5 minutes. Cells were fixed in 
4% paraformaldehyde for 15 minutes before blocking (5% FBS) and permeabilization (0.3% Triton X-100) 
for 1 hour at room temperature. Staining was directed against ETV6 (Sigma Prestige), HDAC3 (Cell Sig-
naling Technologies), Sin3A (Cell Signaling Technologies), NCOR1 (Cell Signaling Technologies), and 
NCOR2 (Abcam) overnight at 4°C. Cells were washed 3 times with 1× PBS (Gibco) before incubation with 
anti-rabbit Alexa Fluor 568 (Life Technologies) for 1 hour at room temperature. Cells were counterstained 
with DAPI, 1 μg/μL (Thermo Fisher Scientific), for 10 minutes at room temperature. Slides were mounted 
with ProLong Antifade mounting media (Thermo Fisher Scientific). Staining specificity was determined by 
omission of  primary antibody. Immunofluorescence image were acquired at ×60, plan apochromat (NA) 
1.4 (Olympus FV1000), and analyzed (FV-Viewer Software, FV10-ASW, version 4.2b). Quantification of  
nuclear and cytoplasmic intensity was measured using the ImageJ macro (NIH) (http://dev.mri.cnrs.fr/
attachments/download/1931/Intensity_Ratio_Nuclei_Cytoplasm.ijm). Images were exported to ImageJ 
(NIH) for final presentation.
Immunoprecipitation. LRS chambers were obtained from consented regular blood donors at Children’s 
Hospital Colorado, Aurora, Colorado, USA. PBMCs were lysed and protein complexes were purified by 
centrifugation. Protein complexes were incubated with rec-Protein G-sepharose beads (Invitrogen) and 
antibodies directed against ETV6 (Sigma Prestige) overnight at 4°C on a rocking platform. After incu-
bation, beads were sequentially washed 3 times with 1× PBS (Gibco). Beads were boiled for 10 minutes 
in 2× SDS-PAGE sample buffer (Bio-Rad) to elute pulldown products for Western blot analysis. Protein 
eluate was run on Tris-Glycine SDS-page gel (Bio-Rad) and transferred to nitrocellulose membranes. Mem-
branes were blocked in tris-buffered saline with 0.1% Tween-20 containing 5% milk at 4°C for 1 hour 
and were probed with HDAC3 (Cell Signaling Technologies), NCOR2 (Abcam), and α-tubulin (Abcam) 
primary antibodies on a shaker at 4°C overnight, followed by 1 hour of  room temperature incubation with 
HRP-conjugated secondary antibodies (Invitrogen). Chemoluminescence was recorded using the automat-
ed Gel Doc XR+ system (Bio-Rad).
PBMC isolation and culture. LRS chambers were obtained from consented regular blood donors at Chil-
dren’s Hospital Colorado. Whole blood was subject to Ficoll-Paque (GE Healthcare) separation for PBMC 
isolation following manufacturer guidelines. Mononuclear cells were counted using Trypan blue exclusion 
and resuspended (1 × 106/mL) and cultured in RPMI 1640 media (Gibco) supplemented with 10% FBS 
(Thermo Fisher Scientific) and 1% Penicillin-Streptomycin (Gibco) and were maintained at 37°C in 5% 
CO2 for 24 hours before electroporation.
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siRNA knockdown. Cultured PBMCs were subject to siRNA knockdown using 50 nM pooled siRNA 
against ETV6 (Dharmacon). Electroporation of  siRNAs was performed using the Neon Transfection system 
(Thermo Fisher Scientific). All electroporation conditions were carried out according to the manufactur-
er’s guidelines (2150 V, 20 ms, 1 pulse). Total protein lysates were collected 48 hours after electroporation 
and resolved on Tris-Glycine SDS-PAGE gels as above. Membranes were probed with antibodies against 
anti-acetylated histone H3 (Cell Signaling Technologies) and total histone H3 (Cell Signaling Technologies).
CD34+ isolation and culture. Deidentified umbilical cord blood units were obtained from ClinImmune, 
Aurora, Colorado, USA. Mononuclear cells were isolated by density gradient centrifugation using Ficoll-
Paque Plus (GE Healthcare). CD34+ cells were affinity purified from using the CD34 Microbead Kit 
(Miltenyi Biotech), resuspended (3 × 104 cells/mL), and cultured in serum-free media containing IMDM 
(Gibco) supplemented with 20% BIT 9500 (Stemcell Technologies), 10 μg/mL LDL (Calbiochem), 55 μM 
2-Mercaptoethanol (Gibco), 1% Penicillin-Streptomycin (Gibco), 2 mM L-glutamine (Gibco), and 50 ng/
mL thrombopoietin (R&D Biosystems).
CD34+ CRISPR deletion. 48 hours after isolation, CD34+ cells were electroporated using the Neon trans-
fection system (Thermo Fisher Scientific) with single guide RNA (sgRNA) directed against ETV6 and 
Cas9 plasmid (Synthego) as previously described (44). Briefly, 1 μg sgRNA and 1 μg Cas9 were complexed 
for 30 minutes at room temperature. The RNP complex electroporated into cells using optimized condi-
tions (1600 V, 10 ms, 3 pulses) (44). Total protein lysates were collected 48 hours after electroporation and 
resolved on Tris-Glycine SDS-PAGE gels (Bio-Rad) as above. Membranes were probed for acetylated his-
tone H3 and total histone H3 as above.
Single-cell RNA-Seq. All ETV6 P214L patients in the cohort were recruited at the Hematology Clinic at Chil-
dren’s Hospital of Michigan. All ETV6 R369Q patients in the cohort were recruited at the Hematology Clinic 
at Children’s Mercy Hospital. Isolated PBMCs were resuspended in 1× PBS (Gibco) with 0.04% weight/volume 
BSA. Chromium Single-cell 3′ Reagent (V2 chemistry) was used for barcoding and cDNA library preparation 
as per the manufacturer’s guidelines, and cDNA was sequenced using the 10× Genomics Single-cell RNA-Seq 
platform at the University of Colorado Genomics Core Facility (BioProject PRJNA657295).
Analysis of  single-cell-Seq. Single-cell RNA-Seq data were initially processed by the Cell Ranger pipeline 
(v2.1.0) from 10× Genomics using the human reference genome (GrCH38). The generated count matrices 
were then analyzed using the Seurat package in R (v3). Read counts were normalized to library size, scaled 
by 10,000, log transformed, and filtered based on the following criteria: cells with less than 250 genes 
detected, proportion of  the UMIs mapped to mitochondrial genes over 0.1, or high HBB gene expression 
were excluded from analysis; genes detected in less than 10 cells were also excluded. Cell-cell variation 
in gene expression driven by the number of  detected molecules and mitochondrial gene expression were 
regressed out using linear regression. Dimensionality reduction, PCA, UMAP projection, and graph-based 
clustering analysis were then performed. Marker genes for each cluster were identified by Wilcoxon rank 
sum test comparing genes expressed in each cluster to all other clusters.
Platelet RNA-Seq. All ETV6 P214L patients in the cohort were recruited at the Hematology Clinic at Chil-
dren’s Hospital of  Michigan. All ETV6 R369Q patients in the cohort were recruited at the Hematology Clinic 
at Children’s Mercy Hospital. Total RNA was isolated from leukoreduced platelet preparations and stored in 
Trizol (Invitrogen) as previously described (45). RNA-seq libraries were prepared and bar-coded using TruSeq 
V2 with oligo selection (Illumina). 50 cycle single-end reads were generated on a single lane of  the HiSeq 2000 
(Illumina) and aligned using Novoalign (Novocraft Technologies) to UCSC genome version hg19 with known 
and shuffled splice junctions. Assignment of  read counts to transcripts was performed using the USeq analysis 
suite. Normalization of  read counts and differential expression analysis was performed with DESeq2 (46). 
Sample-to-sample variability in the level of  leukocyte transcripts, which can significantly alter read counts, 
was corrected for by including the ratio of  PTPRC (leukocyte marker) and CD45/ITGA2B (platelet marker) 
as a factor in the model for significance testing (BioProject PRJNA656812).
PBMC RNA-Seq. Total RNA was isolated using the RNeasy RNA extraction kit (QIAGEN) as per the 
manufacturer’s guidelines. RNA purity and concentration were measured on a NanoDrop (Thermo Fisher 
Scientific). Nugen Universal Plus mRNA-seq Library Preparation (Tecan) was used for next-generation library 
construction per the manufacturer’s protocols. The directional mRNA template libraries were then sequenced 
as paired-end 150 bp reads on the Novaseq 6000 platform at the University of Colorado Genomics Core Facil-
ity. Derived sequences were analyzed by applying a custom computational pipeline consisting of the open-
source gSNAP, Cufflinks, and R for sequence alignment and ascertainment of differential gene expression (47). 
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In short, reads generated were mapped to the human genome (GrCh38) by gSNAP (48), expression (FPKM) 
was derived by Cufflinks (49), and differential expression was analyzed with ANOVA in R. Genes significant at 
an FDR < 0.05 were submitted to pathway analysis using Ingenuity Pathway Analysis (QIAGEN) to identify 
pathways of interest that were modified by ETV6 knockdown (BioProject PRJNA657293).
Immunophenotyping. Isolated PBMCs were examined for cell surface expression by flow cytometry. 
Expression of  surface markers was determined using the following antibodies: CD34 BV421 (BD, clone 
581), CD10 APC (BioLegend, clone HI10a), CD123 BV711 (BD, clone 7G3), CD3 FITC (BioLegend, 
clone HIT3a), CD90 PE (BD, clone 5E10), CD38 CF594 (BD, clone HIT2), CD19 PECy7 (BD, clone 
HIB19), CD20 BV605 (BD, clone 2H7), and CD45RA A700 (BD, clone HI100). Cells were stained for 30 
minutes at 4°C. Single-color controls were obtained using CompBead Anti-Mouse Ig, k/Negative Control 
Compensation Particles (BD Biosciences). Data were acquired on BD FACSAria Cell Sorter and analyzed 
with FlowJo software (BD Biosciences).
Plasma cytokine analysis. All ETV6 P214L patients in the cohort were recruited at the Hematology Clin-
ic at Children’s Hospital of  Michigan. All ETV6 R369Q patients in the cohort were recruited at the Hema-
tology Clinic at Children’s Mercy Hospital. Whole blood was collected into EDTA-treated tubes (BD Bio-
sciences). Cells and platelets were removed by centrifugation for 15 minutes at 2000g at 4°C. 500 μl aliquots 
of  plasma were maintained at –80°C. The V-PLEX Human cytokine 30-Plex kit (Mesoscale Discovery) 
was used to detect Eotaxin, Eotaxin-3, GM-CSF, interferon-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-8 (HA), IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, 
MDC, MIP-1α, MIP-1β, TARC, TNF-α, TNF-β, and VEGF-A as per the manufacturer’s guidelines. Plates 
were read on QuickPlex SQ120 (Mesoscale Discovery).
MK differentiation and proplatelet formation. CD34+ cord blood–derived cells were maintained in serum-free 
media as described above and were analyzed for proplatelet formation 12–14 days after electroporation as pre-
viously described (50). 100,000 cells were plated per replicate, cells demonstrating proplatetets were counted 
(×20 magnification, light microscope) and quantified relative to total cells using Trypan blue exclusion.
RNA-Seq and analysis. Samples were prepared according to library kit manufacturer’s protocol (Illumina), 
indexed, pooled, and sequenced on an Illumina NovaSeq. Base calls and demultiplexing were performed 
with Illumina’s RTA version 1.9 and bcl2fastq2 software with a maximum of  1 mismatch in the indexing 
read. RNA-seq reads were then aligned to the Ensembl release 76 primary assembly with STAR version 
2.5.1a (51). Gene counts were derived from the number of  uniquely aligned unambiguous reads by Sub-
read:featureCount version 1.4.6-p5 (52). Isoform expression of  known Ensembl transcripts was estimated 
with Salmon version 0.8.2 (53). Sequencing performance was assessed for the total number of  aligned reads, 
total number of  uniquely aligned reads, and features detected. The ribosomal fraction, known junction satu-
ration, and read distribution over known gene models were quantified with RSeQC version 2.6.2 (54).
All gene counts were then imported into the R/Bioconductor package EdgeR (55), and TMM normal-
ization size factors were calculated to adjust for samples for differences in library size. Ribosomal genes 
and genes not expressed in the group with the smallest size minus 1 sample greater than 1 count per million 
were excluded from further analysis. The TMM size factors and the matrix of  counts were then imported 
into the R/Bioconductor package Limma (56). Weighted likelihoods based on the observed mean-variance 
relationship of  every gene and sample were then calculated for all samples with the voomWithQuality-
Weights (57). The performance of  all genes was assessed with plots of  the residual SD of  every gene to their 
average log count with a robustly fitted trend line of  the residuals. Differential expression analysis was then 
performed to analyze for differences between conditions, and the results were filtered for only those genes 
with Benjamini-Hochberg FDR-adjusted P values less than or equal to 0.05.
For each contrast extracted with Limma, global perturbations in known Gene ontology (GO) terms, 
MSigDb, and KEGG pathways were detected using the R/Bioconductor package GAGE (58) to test for 
changes in expression of  the reported log2 fold changes reported by Limma in each term versus the back-
ground log2 fold changes of  all genes found outside the respective term. The R/Bioconductor package 
heatmap3 (59) was used to display heatmaps across groups of  samples for each GO or MSigDb term with 
a Benjamini-Hochberg FDR-adjusted P value of  less than or equal to 0.05. Perturbed KEGG pathways 
where the observed log2 fold changes of  genes within the term were significantly perturbed in a single direc-
tion versus background or in any direction compared with other genes within a given term, with P values 
less than or equal to 0.05 were rendered as annotated KEGG graphs with the R/Bioconductor package 
Pathview (60) (BioProject PRJNA657292).
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Data display. Data visualizations were created in GraphPad Prism 8 and Adobe Illustrator (version 
CC 2020). Data are presented as the mean ± SD.
Statistics. Analyses were performed using GraphPad Prism 8. Results were considered statistically sig-
nificant if  the P value was less than 0.05. Normality of  the data were assessed using the Anderson-Darling 
test or Shapiro-Wilk test in cases of  smaller sample size. For tests between 2 groups of  normal data, an 
unpaired t test was used. Mann-Whitney U test was used for data where sample size was too small to assess 
normality. All statistical tests were 2 tailed. Experimental numbers are reported as n = x.
Study approval. All ETV6 P214L patients in the cohort were recruited at the Hematology Clinic at 
Children’s Hospital of  Michigan. All ETV6 R369Q patients in the cohort were recruited at the Hematolo-
gy Clinic at Children’s Mercy Hospital. The study received Institutional Review Board approval from the 
University of  Colorado Anschutz Medical Campus. Deidentified umbilical cord blood units were obtained 
from ClinImmune under protocols approved by the institutional review board of  the University of  Colora-
do. LRS chambers from donors at Children’s Hospital Colorado were obtained under methods approved by 
the institutional review board of  the University of  Colorado. Written informed consent was obtained for all 
participants. Studies were performed in accordance with the Declaration of  Helsinki.
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